(Q33899097)

29 July 2017

1 reference

title

Immunology and immunotherapy of human cancer: present concepts and clinical developments (English)

1 reference

29 July 2017

0 references

1 reference

Bremers AJ

1

1 reference

PubMed ID

10781746

29 July 2017

Parmiani G

series ordinal

2

1 reference

29 July 2017

1 April 2000

1 reference

Critical Reviews in Oncology Hematology

29 July 2017

1 reference

29 July 2017

34

1 reference

29 July 2017

1-25

1 reference

29 July 2017

1

1 reference

Human tumor antigens recognized by T lymphocytes

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

The role of CD4+ T cell responses in antitumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

CD4 T cells and their role in antitumor immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Ligand recognition by alpha beta T cell receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Dendritic cells and the control of immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Why are dendritic cells central to cancer immunotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Receptors for HLA class-I molecules in human natural killer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Regulation of adaptive immunity by natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Antibodies against p53 are associated with poor prognosis of colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Oncogenic proteins as tumor antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

A human natural antibody to adenocarcinoma that inhibits tumour cell migration

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Prospective study of circulating T-lymphocyte subpopulations and disease progression in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Flow cytometric investigation of immune-response-related surface molecules on human colorectal cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Development of immunogenic colorectal cancer cell lines for vaccination: expression of CD80 (B7.1) is not sufficient to restore impaired primary T cell activation in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Induction of antigen-specific T cell anergy: An early event in the course of tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Keeping the immune system alerted against cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Sodium dithiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: clinical results and immunologic correlates of response

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Origin, maturation and antigen presenting function of dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

T cell priming versus T cell tolerance induced by synthetic peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

New use of BCG for recombinant vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Exposing the immunology of naked DNA vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Augmenting the immunogenicity of carbohydrate tumor antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Recent advances in the study of dendritic cells and follicular dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Bacillus Calmette-Guérin mycobacteria stimulate human blood dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Immunotherapy of malignancy by in vivo gene transfer into tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Immunotherapy I: Cyclosine gene transfer strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Cytokine gene transduction in the immunotherapy of cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Prevention of breast tumour development in vivo by downregulation of the p185neu receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Clinical experience with CD64-directed immunotherapy. An overview

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

1 reference

7 January 2021

OK-432 develops CTL and LAK activity in mononuclear cells from regional lymph nodes of lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Significant prognostic factors by multivariate analysis of 3926 gastric cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Phase IB trial of picibanil (OK-432) as an immunomodulator in patients with resected high-risk melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Phase II trial of low dose gamma-interferon in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Phase II trial of recombinant DNA gamma-interferon in advanced colorectal cancer: a Southwest Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Interleukin-2-based immunotherapy and chemoimmunotherapy in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Phase II study of combined levamisole with recombinant interleukin-2 in patients with advanced malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Combined levamisole with recombinant interleukin-2 (IL-2) in patients with advanced renal cell carcinoma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Phase II study of interferon-alpha and all-trans retinoic acid in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Isolated limb perfusion in primary and recurrent melanoma: indications and results

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

MUC-1 epithelial tumor mucin-based immunity and cancer vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Five-year survival in breast cancer treated with adjuvant immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Immunotherapy for colon cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Gene therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Dendritic cell-based immunotherapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

A Phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Immunotherapeutic potential of bispecific antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900059-1

7 January 2021

10.1016/S1040-8428(99)00059-1

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10781746